Menu

Close

Sign InSign Out

Materials

Co-pay Cards & Patient Savings Offers

Request Samples

Hospital Products

Vaccines, Biologics & ​​​​​​​Small-molecule Medicines

Pfizer Oncology Together

Pfizer RxPathways

Events

Materials

Videos

Menu

Close

About

About

IBRANCE experience

Guidelines

Mechanism of action

Dosing & Monitoring

Dosing & Monitoring

Dosing and administration

Monitoring

Recommended dose modifications for IBRANCE

What you need to know about IBRANCE tablets

​​​​​​​Efficacy

IBRANCE + aromatase inhibitor

Primary endpoint

Secondary endpoints

Updated analyses

Subgroup analyses

IBRANCE + fulvestrant​​​​​​​

Primary endpoint

Secondary endpoints

Updated analyses

Subgroup analyses

Safety Data

​​​​​​​IBRANCE + aromatase inhibitor

Adverse reactions

Discontinuations and dose reductions

Neutropenia and lab abnormalities

Warnings and Precautions

​​​​​​​IBRANCE + fulvestrant

Adverse reactions

Discontinuations and dose reductions

Neutropenia and lab abnormalities

Warnings and Precautions

​​​​​​​Real-World Evidence​​​​​​​

​​​​​​​Real-World Evidence​​​​​​​

Introduction

Clinical trial summary

Real-world study design

Real-world study patient characteristics

Real-world effectiveness

​​​​​​Support & Order

​​​​​​Support & Order

Events

Materials

Videos

Coverage and access

Personalized patient support

  • Prescribing Information for Capsules
  • Prescribing Information for Tablets
  • Patient Site
  • Real-World Evidence

    Real-world study patient characteristics

    Real-world evidence complements data from randomized clinical trials. It is important to understand both the randomized clinical trial results and the limitations of this observational retrospective real-world study. 

    Expand here to view

    • Review results from PALOMA-2, the randomized clinical trial that evaluated IBRANCE + letrozole in postmenopausal women with estrogen receptor-positive (ER+)/HER2- mBC and no prior treatment in the metastatic setting
    • Understand the limitations of this observational retrospective real-world study:
      • This study is a retrospective database study of electronic health records, which may have missing or erroneous data entry and cannot determine causal relationship1,2
      • Disease progression was based on the treating physician’s clinical assessment or interpretation of radiographic or pathologic results rather than standard criteria (e.g., Response Evaluation Criteria in Solid Tumors)1,2
      • While stabilized inverse probability treatment weighting and propensity score matching were used to balance baseline and clinical patient characteristics, unobserved variables cannot be fully addressed through these methods1,2
      • Findings presented here may not be generalizable to patient populations not represented in the Flatiron Database1,2
      • Safety data were not collected as part of the study

    Select baseline characteristics

    After sIPTW (N=2709)1,2

    Across treatment arms:
     

    • Median age was 70 years, with ~35% of patients ≥75 years of age and 99% female 
    • 92% of patients were treated in community-based practices
    • 67.5% of patients were White, 8.5% were Black, and 24.0% were another/unknown race
    • In ECOG performance status, 30.4% had a score of 0, 23.0% had a score of 1,15.4% had a score of ≥2, and 31.4% had no documented score

    After sIPTW (N=2709) and 1:1 PSM (N=1878), baseline characteristics were generally similar between both treatment groups.1,2

    ECOG PS=Eastern Cooperative Oncology Group performance status.

    *Multiple metastases at the same site were counted as 1 site.1,2

    Observational retrospective analyses are not intended
    for direct comparison with clinical trials.

    Age and practice type

    Race/ethnicity and ECOG PS

    Disease stage and time to metastatic diagnosis

    Metastatic disease sites

       Race data were not known in the “not documented” race group.1

       Multiple metastases at the same site were counted as 1 site (e.g., if a patient had 3 bone metastases in the spine, it was considered only 1 site).1

    §   ​​​​​​​Visceral disease was defined as metastatic disease in the lung and/or liver; patients could have had other sites of metastases. No visceral disease was defined as no lung or liver metastases.1

    ||  ​​​​​​​ Bone-only disease was defined as metastatic disease in the bone only.1

    Real-world study design and limitations

    Take another look

    NEXT: Real-world effectiveness

    Explore the data


    References:
    1. Rugo HS, Brufsky A, Liu X, et al. Overall survival with first-line palbociclib plus an aromatase inhibitor (AI) vs AI in metastatic breast cancer: a large real-world database analysis. Poster presented at European Society for Medical Oncology (ESMO) Breast Cancer 2022 Congress; May 3-5, 2022; Berlin, Germany. Poster 169P.
    2. Data on file. Pfizer Inc., New York, NY.

    Real-World Evidence

    Neutropenia was the most frequently reported adverse reaction in PALOMA-2 (80%) and PALOMA-3 (83%). In PALOMA-2, Grade 3 (56%) or 4 (10%) decreased neutrophil counts were reported in patients receiving IBRANCE plus letrozole. In PALOMA-3, Grade 3 (55%) or Grade 4 (11%) decreased neutrophil counts were reported in patients receiving IBRANCE plus fulvestrant. Febrile neutropenia has been reported in 1.8% of patients exposed to IBRANCE across PALOMA-2 and PALOMA-3. One death due to neutropenic sepsis was observed in PALOMA-3. Inform patients to promptly report any fever.

    Monitor complete blood count prior to starting IBRANCE, at the beginning of each cycle, on Day 15 of first 2 cycles and as clinically indicated. Dose interruption, dose reduction, or delay in starting treatment cycles is recommended for patients who develop Grade 3 or 4 neutropenia.

    Severe, life-threatening, or fatal interstitial lung disease (ILD) and/or pneumonitis can occur in patients treated with CDK4/6 inhibitors, including IBRANCE when taken in combination with endocrine therapy. Across clinical trials (PALOMA-1, PALOMA-2, PALOMA-3), 1.0% of IBRANCE-treated patients had ILD/pneumonitis of any grade, 0.1% had Grade 3 or 4, and no fatal cases were reported. Additional cases of ILD/pneumonitis have been observed in the post-marketing setting, with fatalities reported.

    Monitor patients for pulmonary symptoms indicative of ILD/pneumonitis (e.g., hypoxia, cough, dyspnea). In patients who have new or worsening respiratory symptoms and are suspected to have developed pneumonitis, interrupt IBRANCE immediately and evaluate the patient. Permanently discontinue IBRANCE in patients with severe ILD or pneumonitis.

    Based on the mechanism of action, IBRANCE can cause fetal harm. Advise females of reproductive potential to use effective contraception during IBRANCE treatment and for at least 3 weeks after the last dose. IBRANCE may impair fertility in males and has the potential to cause genotoxicity. Advise male patients to consider sperm preservation before taking IBRANCE. Advise male patients with female partners of reproductive potential to use effective contraception during IBRANCE treatment and for 3 months after the last dose. Advise females to inform their healthcare provider of a known or suspected pregnancy. Advise women not to breastfeed during IBRANCE treatment and for 3 weeks after the last dose because of the potential for serious adverse reactions in nursing infants. 

    The most common adverse reactions (≥10%) of any grade reported in PALOMA-2 for IBRANCE plus letrozole vs placebo plus letrozole were neutropenia (80% vs 6%), infections (60% vs 42%), leukopenia (39% vs 2%), fatigue (37% vs 28%), nausea (35% vs 26%), alopecia (33% vs 16%), stomatitis (30% vs 14%), diarrhea (26% vs 19%), anemia (24% vs 9%), rash (18% vs 12%), asthenia (17% vs 12%), thrombocytopenia (16% vs 1%), vomiting (16% vs 17%), decreased appetite (15% vs 9%), dry skin (12% vs 6%), pyrexia (12% vs 9%), and dysgeusia (10% vs 5%).

    The most frequently reported Grade ≥3 adverse reactions (≥5%) in PALOMA-2 for IBRANCE plus letrozole vs placebo plus letrozole were neutropenia (66% vs 2%), leukopenia (25% vs 0%), infections (7% vs 3%), and anemia (5% vs 2%).

    Lab abnormalities of any grade occurring in PALOMA-2 for IBRANCE plus letrozole vs placebo plus letrozole were decreased WBC (97% vs 25%), decreased neutrophils (95% vs 20%), anemia (78% vs 42%), decreased platelets (63% vs 14%), increased aspartate aminotransferase (52% vs 34%), and increased alanine aminotransferase (43% vs 30%). 

    The most common adverse reactions (≥10%) of any grade reported in PALOMA-3 for IBRANCE plus fulvestrant vs placebo plus fulvestrant were neutropenia (83% vs 4%), leukopenia (53% vs 5%), infections (47% vs 31%), fatigue (41% vs 29%), nausea (34% vs 28%), anemia (30% vs 13%), stomatitis (28% vs 13%), diarrhea (24% vs 19%), thrombocytopenia (23% vs 0%), vomiting (19% vs 15%), alopecia (18% vs 6%), rash (17% vs 6%), decreased appetite (16% vs 8%), and pyrexia (13% vs 5%).

    The most frequently reported Grade ≥3 adverse reactions (≥5%) in PALOMA-3 for IBRANCE plus fulvestrant vs placebo plus fulvestrant were neutropenia (66% vs 1%) and leukopenia (31% vs 2%). 

    Lab abnormalities of any grade occurring in PALOMA-3 for IBRANCE plus fulvestrant vs placebo plus fulvestrant were decreased WBC (99% vs 26%), decreased neutrophils (96% vs 14%), anemia (78% vs 40%), decreased platelets (62% vs 10%), increased aspartate aminotransferase (43% vs 48%), and increased alanine aminotransferase (36% vs 34%). 

    Avoid concurrent use of strong CYP3A inhibitors. If patients must be administered a strong CYP3A inhibitor, reduce the IBRANCE dose to 75 mg. If the strong inhibitor is discontinued, increase the IBRANCE dose (after 3-5 half-lives of the inhibitor) to the dose used prior to the initiation of the strong CYP3A inhibitor. Grapefruit or grapefruit juice may increase plasma concentrations of IBRANCE and should be avoided. Avoid concomitant use of strong CYP3A inducers. The dose of sensitive CYP3A substrates with a narrow therapeutic index may need to be reduced as IBRANCE may increase their exposure.

    For patients with severe hepatic impairment (Child-Pugh class C), the recommended dose of IBRANCE is 75 mg. The pharmacokinetics of IBRANCE have not been studied in patients requiring hemodialysis

    Please see full Prescribing Information for IBRANCE capsules and tablets.

    IBRANCE (palbociclib) 125 mg capsules and tablets are indicated for the treatment of adult patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer (mBC) in combination with:

    • an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or in men, or
    • fulvestrant in patients with disease progression following endocrine therapy

    INDICATIONS

    IBRANCE (palbociclib) 125 mg capsules and tablets are indicated for the treatment of adult patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer (mBC) in combination with:

    • an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or in men, or
    • fulvestrant in patients with disease progression following endocrine therapy

    Please see full Prescribing Information for IBRANCE capsules and tablets .

    OK. We'll need you to sign in before we can determine if you are aligned with a sales representative.

    If you select 'Yes', you will be required to enter your username and password in the sign-in form  that will appear over this window. 

    Would you like to sign in now?